MedinCell S.A.

MedinCell S.A. is a pharmaceutical company dedicated to creating a diverse array of medical treatments. At the heart of its innovation is the BEPO platform, a unique technology designed for long-acting injectable drugs. This system utilizes specific proprietary copolymers alongside a compatible solvent to effectively dissolve or suspend active pharmaceutical compounds, ensuring their sustained release within the body. The company's clinical pipeline includes several notable projects: mdc-IRM, a subcutaneous injection intended for schizophrenia, which is currently undergoing late-stage (Phase III) clinical trials; mdc-CWM, an intra-articular injection formulated to alleviate pain and inflammation; and mdc-TJK, another subcutaneous injection also targeting schizophrenia, presently in preclinical evaluation. Furthermore, MedinCell's research efforts extend to numerous formulation candidates. These include subcutaneous injections like mdc-WWM for contraception, mdc-ANG for central nervous system conditions, mdc-ELK for depressive disorders, and mdc-GRT for applications in organ transplantation. The firm is also exploring perineural injection options such as mdc-CMV for anesthesia and pain management, and mdc-NVA, also for pain relief. MedinCell S.A. conducts its operations from its base in Jacou, France.